CYP450探针药物血浆清除率变化可能不特异反映体内酶活性改变:如何解读探针鸡尾酒研究结果
该研究采用基于生理的药代动力学(PBPK)工作流程,评估常用CYP探针药物血浆清除率是否直接与CYP酶活性变化成比例(敏感性),以及蛋白结合、血-血浆比和肝血流变化对血浆清除率的影响(特异性)。结果显示探针药物血浆清除率对CYP酶活性变化敏感,但蛋白结合改变可削弱探针特异性,尤其对高蛋白结合探针药物;血-血浆比和肝血流±50%变化仅致血浆清除率变化小于±16%。作者开发R脚本用于校正非代谢决定因素影响,以更准确推断CYP酶活性变化。
要点
- CYP探针药物血浆清除率对酶活性变化敏感,但蛋白结合改变可削弱其特异性。
- 高蛋白结合探针药物受血浆蛋白结合变化影响更大,游离药物分数变化更显著。
- 血-血浆比和肝血流±50%变化对多数探针药物血浆清除率影响有限(小于±16%)。
核心结论
- CYP探针药物血浆清除率变化并非特异地反映CYP酶活性改变,蛋白结合变化可显著影响其特异性。
- 在(病理)生理条件下使用CYP探针药物血浆清除率作为酶活性替代指标时,应校正游离药物分数变化。
研究设计与样本
- 采用基于生理的药代动力学(PBPK)工作流程,评估常用CYP探针药物血浆清除率与CYP酶活性变化的关系。
- 研究未报告具体样本量,为建模分析。
主要发现
- 内在清除率变化-90%至+150%时,探针药物血浆清除率呈近乎成比例变化,但咪达唑仑在CYP3A4诱导大于50%时例外。
- 血浆清除率随游离药物分数变化呈近乎成比例改变,削弱探针特异性,尤其对高蛋白结合探针药物。
- 血-血浆比和肝血流±50%变化导致血浆清除率变化小于±16%,对多数探针药物影响有限,咪达唑仑除外。
关键数值与推荐
- 内在清除率变化-90%至+150%时,血浆清除率近乎成比例变化。
- 血-血浆比和肝血流±50%变化时,血浆清除率变化小于±16%。
临床怎么用
- 在患者群体中使用CYP探针药物血浆清除率推断酶活性时,需考虑并校正游离药物分数变化。
- 研究者可使用本研究报告的R脚本校正非代谢决定因素影响,以更准确评估CYP酶活性变化。
局限性
- 研究基于PBPK建模,未在真实患者中验证。
- 未报告具体样本量及研究人群特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: CYP450 (CYP) phenotyping involves quantifying an individual's plasma clearance of CYP-specific probe drugs, as a proxy for in vivo CYP enzyme activity. It is increasingly applied to study alterations in CYP enzyme activity under various (patho)physiological conditions, such as inflammation, obesity, or pregnancy. The phenotyping approach assumes that changes in plasma clearance of probe drugs are driven by changes in CYP enzyme activity. However, plasma clearance is also influenced by protein binding, blood-to-plasma ratio, and hepatic blood flow, all of which may change under (patho)physiological conditions. METHODS: Using a physiologically based pharmacokinetic (PBPK) workflow, we aimed to evaluate whether the plasma clearance of commonly used CYP probe drugs is indeed directly proportional to alterations in CYP enzyme activity (sensitivity), and to what extent alterations in protein binding, blood-to-plasma ratio, and hepatic blood flow observed under (patho)physiological conditions impact plasma clearance (specificity). RESULTS: Plasma clearance of CYP probe drugs is sensitive to alterations in CYP enzyme activity, since alterations in intrinsic clearance between - 90% and + 150% resulted in near-proportional changes in plasma clearance, except for midazolam in the case of > 50% CYP3A4 induction. However, plasma clearance also changed near-proportionally with alterations in the unbound drug fraction, diminishing probe specificity. This was particularly relevant for high protein-bound probe drugs, as alterations in plasma protein binding resulted in larger relative changes in the unbound drug fraction. Alterations in the blood-to-plasma ratio and hepatic blood flow of ± 50% resulted in plasma clearance changes of less than ± 16%, meaning they limitedly impacted plasma clearance of CYP probe drugs, except for midazolam. In order to correct for the impact of non-metabolic determinants on probe drug plasma clearance, an R script was developed to calculate how much the CYP enzyme activity is actually altered under (patho)physiological conditions, when alterations in the unbound drug fraction, blood-to-plasma ratio, and/or hepatic blood flow also impact probe drug plasma clearance. CONCLUSIONS: As plasma protein binding can change under (patho)physiological conditions, alterations in unbound drug fraction should be accounted for when using CYP probe drug plasma clearance as a proxy for CYP enzyme activity in patient populations. The tool developed in this study can support researchers in determining alterations in CYP enzyme activity in patients with (patho)physiological conditions.
引用
- de Jong LM, van de Kreeke M, Ahmadi M, et al. Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail Studies. Clin Pharmacokinet. 2024. PMID: 39463211. doi:10.1007/s40262-024-01426-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。